dsdsa

product

Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

With our outstanding administration, powerful technical capability and strict top quality handle procedure, we go on to provide our purchasers with reliable good quality, reasonable selling prices and excellent services. We goal at becoming certainly one of your most responsible partners and earning your gratification for Doxorubicin, 80714-61-0, 65-19-0, To achieve reciprocal advantages, our company is widely boosting our tactics of globalization in terms of communication with overseas customers, fast delivery, the best quality and long-term cooperation.
Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai Detail:

Product name Daclatasvir 2HCl
Synonyms N,N’-[[1,1'-Biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid dimethyl ester hydrochloride; BMS 790052
CAS No. 1009119-65-6
Appearance White to pale yellow powder
Molecular Formula C40H50N8O6.2(HCl)
Molecular Weight 811.81
Usage Pharmaceutical Grade for Research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Daclatasvir 2HCl Cas: 1009119-65-6

Items

Standard

Results

Characteristics White to pale yellow powder Pale-yellow powder
Water content ≦1.0% 0.25%
Purity ≧99% 99.7%
Single impurity ≦0.1% 0.06%
Residue on ignition ≦0.1% Complies
Conclusion Complies with the in-house specification.

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai detail pictures

Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai detail pictures

Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai detail pictures


Related Product Guide:

Our growth depends on the superior equipment ,exceptional talents and continuously strengthened technology forces for Manufacturer for Sofosbuvir - Pharmaceutical Grade 1009119-65-6 Daclatasvir For Treatment of Hepatitis C – Yibai , The product will supply to all over the world, such as: Morocco, Singapore, Manila, Based on our guiding principle of quality is the key to development, we continually strive to exceed our customers' expectations. As such, we sincerely invite all interested companies to contact us for future cooperation, We welcome old and new customers to hold hands together for exploring and developing; For more information, please feel free to contact us. Thanks. Advanced equipment, strict quality control, customer-orientation service, initiative summary and improvement of defects and extensive industry experience enable us to guarantee more customer satisfaction and reputation which, in return, brings us more orders and benefits. If you are interested in any of our products, please feel free to contact us. Inquiry or visit to our company are warmly welcome. We sincerely hope to start a win-win and friendly partnership with you. You can see more details in our website.
  • Staff is skilled, well-equipped, process is specification, products meet the requirements and delivery is guaranteed, a best partner!
    5 Stars By Maria from Comoros - 2017.12.31 14:53
    This company can be well to meet our needs on product quantity and delivery time, so we always choose them when we have procurement requirements.
    5 Stars By Amber from Slovak Republic - 2018.06.09 12:42
    Write your message here and send it to us